Process development and preclinical toxicity study for trivalent Typhi/iNTS vaccine

A single vaccine is being designed to protect against both typhoid fever and invasive non-typhoidal Salmonella disease, two bacterial infections that kill tens of thousands of people each year, mostly in sub-Saharan Africa and South Asia. Current vaccines target only one of these diseases, and the second infection—invasive non-typhoidal Salmonella—has no licensed vaccine at all. This project aims to close that gap by combining protection against both pathogens into one shot. The research is moving the vaccine from early development into the preclinical toxicology stage, a mandatory step before it can be tested in humans. If the vaccine passes safety tests and later proves effective in clinical trials, it could become the first licensed product to prevent both diseases simultaneously. That would simplify immunisation programmes in low-resource settings, reduce the burden on fragile health systems, and make the vaccine eligible for purchase through Gavi and UNICEF—organisations that supply vaccines to the world’s poorest countries. The ultimate goal is World Health Organization prequalification, which would allow widespread use in public health campaigns. This is applied, translational research with a clear path to real-world impact.